MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Resources for off-label prescribing may be incomplete

Back to society news Blogs list Cancer blog  


Subscribe To Society News RSS Feed  RSS content feed What is RSS feed?

Resources for off-label prescribing may be incomplete




The resources doctors use to get important information about indications and reimbursement for use of cancer drugs off-label appears to be out-of-date and incomplete, as per a research studyled by scientists in the Duke Comprehensive Cancer Center.

The study, which was funded by the Agency for Healthcare Research and Quality (AHRQ), examined compendia the online and hard copy resources that oncologists and pharmacists use when prescribing medications for diseases other than the ones for which they are FDA-approved and observed that they are sometimes unclear and do not appear to follow systematic methods to review or update evidence.

The scientists published their findings in the February 17, 2009 online issue of the journal Annals of Internal Medicine



Resources for off-label prescribing may be incomplete

"Oncologists and pharmacists use the compendia to guide choice of drugs for cancer patients that are not FDA-approved for use in that patient's disease an example would be bevacizumab or Avastin for brain cancer," said Amy Abernethy, M.D., an oncologist at Duke and lead investigator on the study. "Bevacizumab is approved for use in diseases such as colorectal and lung cancer; it is not FDA-approved for brain tumors, but we have evidence that suggests it could be effective in this population, including peer-evaluated studies".

When a drug is used off label, doctors and pharmacists can refer to the compendia for information on dosage; certain selected compendia can also be used as authoritative sources regarding whether the drug will be covered by Medicare, Abernethy said. Most private insurers also follow suit.

But Abernethy's study observed that the compendia often did not include the most updated information on study findings, and there were significant and confusing differences between the way that common compendia presented and updated information. The scientists looked at six compendia determined to be the most usually utilized, as per a sample of oncology pharmacists and oncologists at Duke and Tufts medical centers.

The compendia varied in a number of ways, including the off-label indications that were included, what was considered as evidence and the level of detail provided about the agent.

"Our study observed that there are some limitations in the way the compendia are currently presented, and there are opportunities to improve the system," Abernethy said. "Determining how to improve it will be the next step for policymakers".


Posted by: Janet    Source




Did you know?
The resources doctors use to get important information about indications and reimbursement for use of cancer drugs off-label appears to be out-of-date and incomplete, as per a research studyled by scientists in the Duke Comprehensive Cancer Center. The study, which was funded by the Agency for Healthcare Research and Quality (AHRQ), examined compendia the online and hard copy resources that oncologists and pharmacists use when prescribing medications for diseases other than the ones for which they are FDA-approved and observed that they are sometimes unclear and do not appear to follow systematic methods to review or update evidence.

Medicineworld.org: Resources for off-label prescribing may be incomplete

Asthma| Hypertension| Medicine Main| Diab french| Diabetes drug info| DruginfoFrench| Type2 diabetes| Create a dust free bedroom| Allergy statistics| Cancer terms| History of cancer| Imaging techniques| Cancer Main| Bladder cancer news| Cervix cancer news| Colon cancer news| Esophageal cancer news| Gastric cancer news| Health news| Lung cancer news| Breast cancer news| Ovarian cancer news| Cancer news|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.